Ethnic Bridging Studies Featured Articles
-
Considerations In Using Foreign Trial Data In U.S. NDA Submissions
8/3/2012
More and more drug companies are finding it financially advantageous to conduct clinical trials in foreign countries and to include data from these trials in NDA submissions. When offshore trials are properly conducted and the data is properly handled, this strategy can accelerate approval and lower the cost of drug development. By Ken Phelps, Camargo Pharmaceutical Services
-
Want To Increase Clinical Trial Participation?
11/18/2011
I recently read an article about drug companies paying hospitals to mine their databases for potential clinical trial participants. Apparently, drug companies, including Pfizer (NYSE: PFE), are willing to pay somewhere between $50,000 to $200,000 per list of patients qualifying for drugmaker clinical trials. By Rob Wright, Chief Editor, Life Science Leader magazine
-
Reinventing Recruitment Of The Minority Population In Clinical Research Trials
8/1/2011
The field of clinical research starts and ends with the patient volunteer. Unfortunately, there is a paucity of research volunteers for participation in clinical trials. Patient volunteers are increasingly scarce and even more limited when it comes to minority patient participation in clinical research trials. By Ruthie Barreau